Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Tirzepatide may prevent type 2 diabetes in adults with obesity and prediabetes
Last updated September 12, 2026
Key finding
Tirzepatide treatment was associated with a 90% to 99% reduction in new-onset T2D.
This study analyzed the effects of Tirzepatide on preventing type 2 diabetes in adults with obesity and prediabetes, showing significant reductions in new-onset diabetes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study analyzed the effects of Tirzepatide on preventing type 2 diabetes in adults with obesity and prediabetes, showing significant reductions in new-onset diabetes.
Clinical relevance
The findings highlight the potential of Tirzepatide as a preventive treatment for type 2 diabetes, which is crucial given the rising prevalence of obesity and prediabetes. Effective prevention strategies can significantly reduce the burden of diabetes-related complications and improve public health outcomes.
Keep in mind
The analysis is post hoc, which may limit the robustness of the findings. Sample size and demographic diversity were not detailed, affecting generalizability. The study did not provide effect sizes for all outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Rodolfo JG, Georgios KD, Adam S, et al. Tirzepatide Treatment for Prevention of Type 2 Diabetes in Adults with Obesity and Prediabetes: A Post Hoc Analysis. Journal of the Endocrine Society. 2026;10(9):bvag190. doi:10.1210/jendso/bvag190
Main Effects
Tirzepatide treatment was associated with a 90% to 99% reduction in new-onset type 2 diabetes in high-risk groups.
In the placebo group, 30 participants (14.6%) developed type 2 diabetes.
The OGTT 1-h glucose criterion had a sensitivity of 0.83.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Incident diabetes risk, Negative predictive value of FSG criterion, Negative predictive value of HbA1c criterion, and 10 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Incident diabetes risk
- Negative predictive value of FSG criterion
- Negative predictive value of HbA1c criterion
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
13
Evidence pairs
13
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
13
Evidence pairs
100
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 13 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
GLP-1 Receptor Agonists
matched_intervention
Core evidence
Study findings
The primary outcomes reported in this study.
Negative predictive value of FSG criterion
Tirzepatide → Negative predictive value of FSG criterion
Tirzepatide → Negative predictive value of FSG criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerNegative predictive value of HbA1c criterion
Tirzepatide → Negative predictive value of HbA1c criterion
Tirzepatide → Negative predictive value of HbA1c criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerNegative predictive value of OGTT 1-h glucose criterion
Tirzepatide → Negative predictive value of OGTT 1-h glucose criterion
Tirzepatide → Negative predictive value of OGTT 1-h glucose criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPositive predictive value of FSG criterion
Tirzepatide → Positive predictive value of FSG criterion
Tirzepatide → Positive predictive value of FSG criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPositive predictive value of HbA1c criterion
Tirzepatide → Positive predictive value of HbA1c criterion
Tirzepatide → Positive predictive value of HbA1c criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPositive predictive value of OGTT 1-h glucose criterion
Tirzepatide → Positive predictive value of OGTT 1-h glucose criterion
Tirzepatide → Positive predictive value of OGTT 1-h glucose criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSensitivity of FSG criterion
Tirzepatide → Sensitivity of FSG criterion
Tirzepatide → Sensitivity of FSG criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSensitivity of HbA1c criterion
Tirzepatide → Sensitivity of HbA1c criterion
Tirzepatide → Sensitivity of HbA1c criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSensitivity of OGTT 1-h glucose criterion
Tirzepatide → Sensitivity of OGTT 1-h glucose criterion
Tirzepatide → Sensitivity of OGTT 1-h glucose criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSpecificity of FSG criterion
Tirzepatide → Specificity of FSG criterion
Tirzepatide → Specificity of FSG criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSpecificity of HbA1c criterion
Tirzepatide → Specificity of HbA1c criterion
Tirzepatide → Specificity of HbA1c criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSpecificity of OGTT 1-h glucose criterion
Tirzepatide → Specificity of OGTT 1-h glucose criterion
Tirzepatide → Specificity of OGTT 1-h glucose criterion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Tirzepatide reduced the incidence of type 2 diabetes by 90% to 99% in high-risk adults.
- 30 participants in the placebo group developed diabetes, indicating a significant difference.
- The OGTT 1-h glucose criterion showed a sensitivity of 0.83.
Who this applies to
- Adults with obesity and prediabetes.
- Individuals at high risk for developing type 2 diabetes.
Keep in Mind
- Results are based on a post hoc analysis, which may introduce bias.
- The findings may not be applicable to all populations due to limited demographic data.
- Further studies are needed to confirm the long-term effects of Tirzepatide.
Between the Lines
- The analysis is post hoc, which may limit the robustness of the findings.
- Sample size and demographic diversity were not detailed, affecting generalizability.
- The study did not provide effect sizes for all outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Incident diabetes risk, GLP-1 Receptor Agonists and Negative predictive value of FSG criterion.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
1 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Incident diabetes risk Evidence Hub
All studies measuring Incident diabetes risk
1 studies
outcome_hubMeasures Incident diabetes risk as a key outcome.
Negative predictive value of FSG criterion Evidence Hub
All studies measuring Negative predictive value of FSG criterion
1 studies
outcome_hubMeasures Negative predictive value of FSG criterion as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and Incident diabetes risk
Intervention: TirzepatideOutcome: Incident diabetes risk
1 results
All studies on Tirzepatide and Negative predictive value of FSG criterion
Intervention: TirzepatideOutcome: Negative predictive value of FSG criterion
1 results
All studies on Tirzepatide
Intervention: Tirzepatide
1 results
All studies measuring Incident diabetes risk
Outcome: Incident diabetes risk
1 results
All studies measuring Negative predictive value of FSG criterion
Outcome: Negative predictive value of FSG criterion
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Tirzepatide reduce incident diabetes risk?
Emerging Evidence
Tirzepatide appears to reduce incident diabetes risk.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Incident diabetes risk
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Tirzepatide improve negative predictive value of fsg criterion?
Emerging Evidence
Tirzepatide appears to improve negative predictive value of fsg criterion.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Negative predictive value of FSG criterion
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Tirzepatide improve negative predictive value of HbA1c criterion?
Emerging Evidence
Tirzepatide appears to improve negative predictive value of HbA1c criterion.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Negative predictive value of HbA1c criterion
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Tirzepatide improve negative predictive value of ogtt 1-h glucose criterion?
Emerging Evidence
Tirzepatide appears to improve negative predictive value of ogtt 1-h glucose criterion.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Negative predictive value of OGTT 1-h glucose criterion
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Tirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves weight loss and cardiometabolic healthTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesTirzepatide improves glycemic control and weight loss in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.